Figure 5.
Mean difference in BMD from placebo at 36 months, denosumab vs. placebo, in men with prostate cancer receiving ADT: subgroup analyses.127
Notes: Results are presented as least-squares means.
Mean difference in BMD from placebo at 36 months, denosumab vs. placebo, in men with prostate cancer receiving ADT: subgroup analyses.127
Notes: Results are presented as least-squares means.